A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable Responses in Patients with HER2-mutated MBC By Ogkologos - January 29, 2025 611 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SGNTUC-019 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Sotorasib in Combination with Panitumumab Results in Longer PFS in Patients... December 6, 2023 ESMO Issues First Recommendations on Using Next-Generation Sequencing for Advanced Cancers... August 24, 2020 No Improvement in OS or PFS from Sacituzumab Govitecan Compared with... March 24, 2025 Groundbreaking Trial Results Expand Treatment Options for Some People with Bladder... November 30, 2023 Load more HOT NEWS COVID-19 in people with cancer – what we know so far Mom Unknowingly Has Cancer For 3 Years After Doctor Keeps Telling... New Drugs, New Side Effects: Complications of Cancer Immunotherapy Beating the Heat with Beets
